TrialAnnals of the rheumatic diseases2016

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.

Cem Gabay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.